US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Bicara Therapeutics

14.81

+0.27001.86%

Pre-market: 14.30-0.5100-3.44%04:29 EDT

Volume:596.27K

Turnover:8.80M

Market Cap:807.49M

PE:-3.66

High:15.08

Open:14.56

Low:13.91

Close:14.54

Loading ...

Overview Company News Filings

Bicara Therapeutics Highlights Broad Potential of Ficerafusp Alfa at AACR Annual Meeting 2025

Wedbush Trims Price Target on Bicara Therapeutics to $30 From $31, Keeps Outperform Rating

MT Newswires Live

Bicara Therapeutics to Present Updated Data from Ongoing Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Bicara Therapeutics Initiated at Underweight by Wells Fargo

Wells Fargo Initiates Bicara Therapeutics at Underweight With $8 Price Target

MT Newswires Live

Truist biotech analyst holds an analyst/industry conference call

Bicara Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Bicara Therapeutics Inc : H.c. Wainwright Cuts Target Price to $44 From $45

THOMSON REUTERS

Bicara Therapeutics Q4 2024 GAAP EPS $(0.39) Misses $(0.33) Estimate, Cash Balance Of $490M To Fund Operations Into The First Half Of 2029

BRIEF-Bicara Therapeutics Inc QTRLY Loss Per Share $0.39

Bicara Therapeutics Inc: Qtrly Loss per Share $0.39

THOMSON REUTERS

Bicara Therapeutics Inc: Co Expects Its Existing Cash and Cash Equivalents Will Fund Operations Into H1 of 2029

THOMSON REUTERS

Press Release: Bicara Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Bicara Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2025

Bicara Therapeutics Price Target Maintained With a $13.01/Share by Cantor Fitzgerald

Bicara Therapeutics Price Target Maintained With a $31.00/Share by Wedbush

Bicara Therapeutics Inc - Phase 2/3 Trial to Enroll Approximately 650 Patients

THOMSON REUTERS

Bicara Therapeutics Announces First Patients Enrolled in Fortifi-Hn01, a Pivotal Phase 2/3 Clinical Trial of Ficerafusp Alfa in 1L Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

THOMSON REUTERS

Bicara Therapeutics Inc - Primary Endpoints Include Overall Response Rate and Survival

THOMSON REUTERS

Bicara Therapeutics Announces First Patients Enrolled in FORTIFI-HN01, a Pivotal Phase 2/3 Clinical Trial of Ficerafusp Alfa in 1L Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BCAX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BCAX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BCAX\",,,,,undefined,":{"symbol":"BCAX","market":"US","secType":"STK","nameCN":"Bicara Therapeutics","latestPrice":14.81,"timestamp":1745870400000,"preClose":14.54,"halted":0,"volume":596265,"hourTrading":{"tag":"盘前","latestPrice":14.3,"preClose":14.81,"latestTime":"04:29 EDT","volume":6,"amount":89.03999999999999,"timestamp":1745915376050},"delay":0,"floatShares":28372221,"shares":54523326,"eps":-4.045991,"marketStatus":"Pre-Mkt","change":0.27,"latestTime":"04-29 06:58:40 EDT","open":14.56,"high":15.08,"low":13.9064,"amount":8799802.5668,"amplitude":0.080715,"askPrice":22,"askSize":200,"bidPrice":5.93,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-4.045991,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1745933400000},"marketStatusCode":1,"adr":0,"listingDate":1726200000000,"exchange":"NASDAQ","adjPreClose":14.81,"preHourTrading":{"tag":"盘前","latestPrice":14.3,"preClose":14.81,"latestTime":"04:29 EDT","volume":6,"amount":89.03999999999999,"timestamp":1745915376050},"postHourTrading":{"tag":"盘后","latestPrice":14.81,"preClose":14.81,"latestTime":"16:05 EDT","volume":1146,"amount":16972.26,"timestamp":1745870706681},"volumeRatio":1.0253467952275421,"impliedVol":0.5103,"impliedVolPercentile":0.3333},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BCAX\",,,,,undefined,":{"symbol":"BCAX","floatShares":28372221,"roa":"-13.84%","roe":"-19.14%","lyrEps":-4.045991,"volumeRatio":1.0253467952275421,"shares":54523326,"dividePrice":0,"high":15.08,"amplitude":0.080715,"preClose":14.54,"low":13.9064,"week52Low":8.91,"pbRate":"1.64","week52High":28.09,"institutionHeld":0,"latestPrice":14.81,"eps":-4.045991,"divideRate":0,"volume":596265,"delay":0,"ttmEps":-4.045991,"open":14.56,"prevYearClose":17.42,"prevWeekClose":14.54,"prevMonthClose":13.03,"prevQuarterClose":13.03,"fiveDayClose":12.65,"twentyDayClose":13.4,"sixtyDayClose":12.91},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BCAX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2531267717","title":"Bicara Therapeutics Highlights Broad Potential of Ficerafusp Alfa at AACR Annual Meeting 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2531267717","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531267717?lang=en_us&edition=fundamental","pubTime":"2025-04-29 04:01","pubTimestamp":1745870460,"startTime":"0","endTime":"0","summary":"BOSTON, April 28, 2025  -- Bicara Therapeutics Inc. , a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced multiple presentations related to ficerafusp alfa at the American Association for Cancer Research  Annual Meeting 2025. Ficerafusp alfa is a first-in-class bifunctional antibody that combines two clinically validated targets: an epidermal growth factor receptor  directed monoclonal antibody with a domain that binds to human transforming growth factor beta  and is being evaluated across multiple solid tumor types.Dual blockade of EGFR and TGF-β with ficerafusp alfa has the potential to overcome resistance mechanisms in 1L R/M HNSCC in combination with pembrolizumab. Spatial transcriptomics revealed downregulation of epithelial-mesenchymal transition and hypoxia pathways in human papillomavirus-negative tumors with ficerafusp alfa and pembrolizumab, supporting the potential role of TGF-β","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bicara-therapeutics-highlights-broad-potential-200100551.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BCAX","ORR"],"gpt_icon":0},{"id":"2530747420","title":"Wedbush Trims Price Target on Bicara Therapeutics to $30 From $31, Keeps Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2530747420","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530747420?lang=en_us&edition=fundamental","pubTime":"2025-04-28 19:18","pubTimestamp":1745839086,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics (BCAX) has an average rating of overweight and mean price target of $33.40, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research fro","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BCAX"],"gpt_icon":0},{"id":"2529680370","title":"Bicara Therapeutics to Present Updated Data from Ongoing Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2529680370","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529680370?lang=en_us&edition=fundamental","pubTime":"2025-04-23 22:00","pubTimestamp":1745416800,"startTime":"0","endTime":"0","summary":"Title: Ficerafusp alfa with pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: Updated results from an expansion cohort of an open-label, multicenter, phase 1/1b trial. Session Date and Time: 6/1/2025 12:12 - 12:18 p.m. CT. Following the meeting, the presentation will be available on Bicara’s website at www.bicara.com.About Ficerafusp AlfaFicerafusp alfa is a first-in-class bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor  directed monoclonal antibody with a domain that binds to human transforming growth factor beta . Through this dual-targeting mechanism, ficerafusp alfa has the potential to exert potent anti-tumor activity by simultaneously blocking both cancer cell-intrinsic EGFR survival and proliferation, as well as the immunosuppressive TGF-b signaling within the tumor microenvironment.About Bicara Therapeutics Bicara Therapeutics is a clinical-stage biopharmaceutical company commi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bicara-therapeutics-present-updated-data-140000054.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4107","BCAX","BK4117","BK4139","AFG"],"gpt_icon":0},{"id":"2528719587","title":"Bicara Therapeutics Initiated at Underweight by Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2528719587","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528719587?lang=en_us&edition=fundamental","pubTime":"2025-04-17 20:12","pubTimestamp":1744891920,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BCAX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 17, 2025 08:12 ET (12:12 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCAX"],"gpt_icon":0},{"id":"2528718572","title":"Wells Fargo Initiates Bicara Therapeutics at Underweight With $8 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2528718572","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528718572?lang=en_us&edition=fundamental","pubTime":"2025-04-17 19:17","pubTimestamp":1744888670,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics (BCAX) has an average rating of overweight and mean price target of $35.83, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research fro","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BCAX","WFC"],"gpt_icon":0},{"id":"2528220864","title":"Truist biotech analyst holds an analyst/industry conference call","url":"https://stock-news.laohu8.com/highlight/detail?id=2528220864","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528220864?lang=en_us&edition=fundamental","pubTime":"2025-04-17 04:25","pubTimestamp":1744835110,"startTime":"0","endTime":"0","summary":"Biotech Analyst Goonewardene, along with head and neck key opinion leader Dr. Perez (Sarah Cannon) (relevant companies MRUS BCAX EXEL) participate ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/truist-biotech-analyst-holds-an-analyst-industry-conference-call-4?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/truist-biotech-analyst-holds-an-analyst-industry-conference-call-4?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BCAX"],"gpt_icon":0},{"id":"2525014957","title":"Bicara Therapeutics Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2525014957","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525014957?lang=en_us&edition=fundamental","pubTime":"2025-04-07 19:32","pubTimestamp":1744025520,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BCAX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 07, 2025 07:32 ET (11:32 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCAX"],"gpt_icon":0},{"id":"2525181620","title":"Bicara Therapeutics Inc : H.c. Wainwright Cuts Target Price to $44 From $45","url":"https://stock-news.laohu8.com/highlight/detail?id=2525181620","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525181620?lang=en_us&edition=fundamental","pubTime":"2025-04-07 18:06","pubTimestamp":1744020402,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250407:nAZN3O5D1S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BCAX","BK4139"],"gpt_icon":0},{"id":"2522371172","title":"Bicara Therapeutics Q4 2024 GAAP EPS $(0.39) Misses $(0.33) Estimate, Cash Balance Of $490M To Fund Operations Into The First Half Of 2029","url":"https://stock-news.laohu8.com/highlight/detail?id=2522371172","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522371172?lang=en_us&edition=fundamental","pubTime":"2025-03-27 19:40","pubTimestamp":1743075633,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics Q4 2024 GAAP EPS $(0.39) Misses $(0.33) Estimate, Cash Balance Of $490M To Fund Operations Into The First Half Of 2029","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44511498/bicara-therapeutics-q4-2024-gaap-eps-0-39-misses-0-33-estimate-cash-balance-of-490m-to-fund-operati","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCAX"],"gpt_icon":0},{"id":"2522371306","title":"BRIEF-Bicara Therapeutics Inc QTRLY Loss Per Share $0.39","url":"https://stock-news.laohu8.com/highlight/detail?id=2522371306","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522371306?lang=en_us&edition=fundamental","pubTime":"2025-03-27 19:38","pubTimestamp":1743075485,"startTime":"0","endTime":"0","summary":"BRIEF-Bicara Therapeutics Inc QTRLY Loss Per Share $0.39March 27 (Reuters) - Bicara Therapeutics Inc BCAX.O:BICARA THERAPEUTICS INC: QTRLY LOSS PER SHARE $0.39BICARA THERAPEUTICS INC: CO EXPECTS ITS E","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nFWN3QA135:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCAX","BK4139"],"gpt_icon":0},{"id":"2522371824","title":"Bicara Therapeutics Inc: Qtrly Loss per Share $0.39","url":"https://stock-news.laohu8.com/highlight/detail?id=2522371824","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522371824?lang=en_us&edition=fundamental","pubTime":"2025-03-27 19:36","pubTimestamp":1743075391,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nFWN3QA135:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BCAX","BK4139"],"gpt_icon":0},{"id":"2522371371","title":"Bicara Therapeutics Inc: Co Expects Its Existing Cash and Cash Equivalents Will Fund Operations Into H1 of 2029","url":"https://stock-news.laohu8.com/highlight/detail?id=2522371371","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522371371?lang=en_us&edition=fundamental","pubTime":"2025-03-27 19:36","pubTimestamp":1743075391,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nFWN3QA135:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BCAX"],"gpt_icon":0},{"id":"2522990371","title":"Press Release: Bicara Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2522990371","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522990371?lang=en_us&edition=fundamental","pubTime":"2025-03-27 19:30","pubTimestamp":1743075000,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update. Dosing commenced in FORTIFI-HN01, a pivotal Phase 2/3 trial of ficerafusp alfa in 1L R/M HNSCC. Updated data from ongoing Phase 1/1b trial in 1L R/M HNSCC to be presented at 2025 ASCO Annual Meeting. Strong financial position with approximately $490 million in cash and cash equivalents expected to fund operations into the first half of 2029. BOSTON, March 27, 2025  -- Bicara Therapeutics Inc. , a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced financial results for the fourth quarter and full year ended December 31, 2024 and provided a business update.Bicara is developing ficerafusp alfa, a first-in-class, dual-action bifunctional epidermal growth factor receptor /transforming growth factor beta  antibody for multiple different solid tumor cancer types.-- In February 2025, Bicara","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCAX"],"gpt_icon":0},{"id":"2522833005","title":"Bicara Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2522833005","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522833005?lang=en_us&edition=fundamental","pubTime":"2025-03-26 04:45","pubTimestamp":1742935500,"startTime":"0","endTime":"0","summary":"BOSTON, March 25, 2025  -- Bicara Therapeutics Inc. , a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that three abstracts relating to the company’s lead product candidate, ficerafusp alfa, will be presented at the American Association for Cancer Research  Annual Meeting 2025, which will be held from April 25-30, 2025 in Chicago, IL. Ficerafusp alfa is a first-in-class bifunctional antibody that combines two clinically validated targets: an epidermal growth factor receptor  directed monoclonal antibody with a domain that binds to human transforming growth factor beta  and is being evaluated across multiple solid tumor types.Details of the poster presentations are as follows:. Location: McCormick Place Convention Center, Poster Section 49. About Bicara Therapeutics Bicara Therapeutics is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bicara-therapeutics-announces-upcoming-presentations-204500281.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BCAX","BK4139"],"gpt_icon":0},{"id":"2519859430","title":"Bicara Therapeutics Price Target Maintained With a $13.01/Share by Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2519859430","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519859430?lang=en_us&edition=fundamental","pubTime":"2025-03-13 23:59","pubTimestamp":1741881540,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BCAX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 13, 2025 11:59 ET (15:59 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCAX"],"gpt_icon":0},{"id":"2511840304","title":"Bicara Therapeutics Price Target Maintained With a $31.00/Share by Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2511840304","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511840304?lang=en_us&edition=fundamental","pubTime":"2025-02-13 00:07","pubTimestamp":1739376420,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BCAX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 12, 2025 11:07 ET (16:07 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCAX"],"gpt_icon":0},{"id":"2510515352","title":"Bicara Therapeutics Inc - Phase 2/3 Trial to Enroll Approximately 650 Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2510515352","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510515352?lang=en_us&edition=fundamental","pubTime":"2025-02-12 05:01","pubTimestamp":1739307681,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250211:nTUA2FQT4X:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BCAX"],"gpt_icon":0},{"id":"2510435255","title":"Bicara Therapeutics Announces First Patients Enrolled in Fortifi-Hn01, a Pivotal Phase 2/3 Clinical Trial of Ficerafusp Alfa in 1L Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2510435255","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510435255?lang=en_us&edition=fundamental","pubTime":"2025-02-12 05:01","pubTimestamp":1739307681,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250211:nTUA2FQT4X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BCAX","BK4139"],"gpt_icon":0},{"id":"2510035251","title":"Bicara Therapeutics Inc - Primary Endpoints Include Overall Response Rate and Survival","url":"https://stock-news.laohu8.com/highlight/detail?id=2510035251","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510035251?lang=en_us&edition=fundamental","pubTime":"2025-02-12 05:01","pubTimestamp":1739307681,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250211:nTUA2FQT4X:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BCAX","BK4139"],"gpt_icon":0},{"id":"2510357545","title":"Bicara Therapeutics Announces First Patients Enrolled in FORTIFI-HN01, a Pivotal Phase 2/3 Clinical Trial of Ficerafusp Alfa in 1L Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2510357545","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510357545?lang=en_us&edition=fundamental","pubTime":"2025-02-12 05:01","pubTimestamp":1739307660,"startTime":"0","endTime":"0","summary":"BOSTON, Feb.  11, 2025  (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/11/3024582/0/en/Bicara-Therapeutics-Announces-First-Patients-Enrolled-in-FORTIFI-HN01-a-Pivotal-Phase-2-3-Clinical-Trial-of-Ficerafusp-Alfa-in-1L-Recurrent-Metastatic-Head-and-Neck-Squamous-Cell-C.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCAX","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":40,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BCAX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-27","symbol":"BCAX","fiscalQuarterEnding":"2024/12","expectedEps":-0.31,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1743048000000,"reportTimeType":"pre","actualEps":-0.39},{"market":"US","date":"2024-11-12","symbol":"BCAX","fiscalQuarterEnding":"2024/09","expectedEps":-0.46,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":-1.6}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BCAX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BCAX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2857,"buy":0.5714,"hold":0,"sell":0.1429,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5714,"analysts":7,"updateTime":1745121600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/BCAX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"BCAX","date":"2025-04-25","current":-12.533268,"percent":0.588235,"low":-22.704836,"twenty":-19.02049,"median":-15.045308,"eighty":-11.297018,"high":-7.513546,"avg":-15.029169,"sd":3.978013,"marketCap":852199585},"quantilePoints":[{"date":"2024-09-13","current":-12.837909,"twenty":-12.837909,"median":-12.837909,"eighty":-12.837909,"marketCap":832435719},{"date":"2024-09-20","current":-20.633135,"twenty":-21.391361,"median":-20.283845,"eighty":-14.007791,"marketCap":1337893755},{"date":"2024-09-27","current":-21.555755,"twenty":-21.594337,"median":-21.446718,"eighty":-19.006626,"marketCap":1397718272},{"date":"2024-10-04","current":-19.962139,"twenty":-21.575885,"median":-21.337681,"eighty":-19.559541,"marketCap":1294385015},{"date":"2024-10-11","current":-15.936161,"twenty":-21.540658,"median":-20.570229,"eighty":-18.732598,"marketCap":1033332575},{"date":"2024-10-18","current":-17.143955,"twenty":-21.466848,"median":-20.283845,"eighty":-16.808457,"marketCap":1111648307},{"date":"2024-10-25","current":-18.964032,"twenty":-21.403103,"median":-19.23243,"eighty":-16.959431,"marketCap":1229665764},{"date":"2024-10-31","current":-19.878264,"twenty":-21.362844,"median":-19.23243,"eighty":-17.02653,"marketCap":1288946422},{"date":"2024-11-08","current":-19.79439,"twenty":-21.337681,"median":-19.82794,"eighty":-17.143955,"marketCap":1283507830},{"date":"2024-11-15","current":-20.345116,"twenty":-21.127995,"median":-19.949558,"eighty":-18.418848,"marketCap":1210086831},{"date":"2024-11-22","current":-16.257533,"twenty":-21.102833,"median":-19.82794,"eighty":-17.143955,"marketCap":966965549},{"date":"2024-11-29","current":-19.02049,"twenty":-20.975343,"median":-19.458892,"eighty":-17.009755,"marketCap":1131300719},{"date":"2024-12-06","current":-17.876882,"twenty":-20.695202,"median":-19.01323,"eighty":-17.12047,"marketCap":1063281195},{"date":"2024-12-13","current":-16.509127,"twenty":-20.532485,"median":-19.005969,"eighty":-17.12047,"marketCap":981929844},{"date":"2024-12-20","current":-15.187116,"twenty":-20.493904,"median":-18.892739,"eighty":-16.769874,"marketCap":903299275},{"date":"2024-12-27","current":-17.49263,"twenty":-20.458153,"median":-18.854995,"eighty":-16.764842,"marketCap":1040426635},{"date":"2025-01-03","current":-15.484454,"twenty":-20.399979,"median":-18.727694,"eighty":-16.641786,"marketCap":920984351},{"date":"2025-01-10","current":-13.952019,"twenty":-20.332862,"median":-18.565256,"eighty":-16.325863,"marketCap":829838189},{"date":"2025-01-17","current":-10.868852,"twenty":-20.271506,"median":-18.306879,"eighty":-15.951961,"marketCap":646457553},{"date":"2025-01-24","current":-10.951191,"twenty":-20.22215,"median":-18.224539,"eighty":-15.55307,"marketCap":651354959},{"date":"2025-01-31","current":-11.811185,"twenty":-20.138275,"median":-17.666458,"eighty":-14.949245,"marketCap":702505641},{"date":"2025-02-07","current":-11.52757,"twenty":-20.11652,"median":-17.561246,"eighty":-13.156068,"marketCap":685636799},{"date":"2025-02-14","current":-12.003311,"twenty":-19.978914,"median":-17.49263,"eighty":-12.003311,"marketCap":713932921},{"date":"2025-02-21","current":-12.643731,"twenty":-19.965494,"median":-17.085242,"eighty":-11.997822,"marketCap":752023854},{"date":"2025-02-28","current":-11.307997,"twenty":-19.942009,"median":-16.815614,"eighty":-11.891694,"marketCap":672577050},{"date":"2025-03-07","current":-14.409462,"twenty":-19.890007,"median":-16.73236,"eighty":-11.891694,"marketCap":857045999},{"date":"2025-03-14","current":-12.213735,"twenty":-19.838005,"median":-16.60519,"eighty":-11.893524,"marketCap":726448513},{"date":"2025-03-21","current":-11.975864,"twenty":-19.8011,"median":-16.394587,"eighty":-11.882546,"marketCap":712300452},{"date":"2025-03-28","current":-10.745093,"twenty":-19.525992,"median":-16.092853,"eighty":-11.882546,"marketCap":730612568},{"date":"2025-04-04","current":-9.486153,"twenty":-19.364339,"median":-15.936742,"eighty":-11.721526,"marketCap":645010946},{"date":"2025-04-11","current":-8.139007,"twenty":-19.311424,"median":-15.55307,"eighty":-11.500123,"marketCap":553411758},{"date":"2025-04-17","current":-9.430022,"twenty":-19.133936,"median":-15.269456,"eighty":-11.355571,"marketCap":641194313},{"date":"2025-04-25","current":-12.533268,"twenty":-19.02049,"median":-15.045308,"eighty":-11.297018,"marketCap":852199585}],"updateTime":1745909291425}}}